AGC BIOLOGICS ENLARGES PDNA AND MRNA MANUFACTURING CAPACITY AT HEIDELBERG FACILITY

KUALA LUMPUR, Sept 15 (Bernama) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.

With this expansion, AGC Biologics is boosting its current 100L and 1,000L manufacturing capacities for a variety of different biologics projects by adding an additional GMP manufacturing line.

The expansion includes a new GMP cleanroom for mRNA development and manufacturing, a new process development lab for microbial protein and cell and gene therapy projects, and additional warehouse capacity. The facility's new capabilities will be fully operational in 2023.

“This investment helps strengthen our existing pDNA capabilities and supports our entry into the mRNA space,” says AGC Biologics Chief Executive Officer, Patricio Massera in a statement.

“With the global pDNA and mRNA markets experiencing record growth, we are focused on ensuring our facilities worldwide offer innovative services that meet the needs of therapeutics developers.”

This is the latest in a series of investments AGC Biologics has made this year to expand its offerings and global footprint.

The company broke ground on a new multipurpose facility in Copenhagen, Denmark in August that will grow AGC Biologics’ global capacity.

Earlier this year, the company expanded its Cell and Gene Therapy Facility in Milan, Italy as well, adding additional capacity and viral vector suspension capabilities.

To learn more, visit www.agcbio.com.

-- BERNAMA